A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma

A personalized neoantigen peptide vaccine formulated with Montanide plus poly-ICLC and administered with local ipilimumab plus systemic nivolumab induces robust neoepitope-specific T cell responses and reshapes the T cell repertoire in blood and tumor.

Read the full article here

Related Articles

Home: Cell Press

Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron,…